Written by the Nuvirox Research Team
Key points
- CALERIE is the only long randomized trial of sustained calorie restriction in healthy, non-obese adults. Participants aimed for 25% restriction and achieved roughly 12% over two years.
- The intervention slowed one measure of biological ageing (DunedinPACE) by 2–3%, and had no significant effect on two other widely used epigenetic clocks.
- That divergence is the most informative result in the trial, and it is usually left out of the summaries.
Short answer: yes, measurably — but by a small amount, on one measurement out of three, over two years. Calorie restriction extends lifespan in rodents with some consistency and in primates with considerable argument. The Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy trial (CALERIE 2) is the only attempt to test it properly in healthy humans, and the result was a 2–3% slowing of the pace of biological ageing on the DunedinPACE algorithm, with no significant change on the PhenoAge or GrimAge clocks. Whether that constitutes evidence that calorie restriction slows human ageing depends heavily on how much you trust the one clock that moved.
CALERIE 2 outcomes across three DNA methylation measures. Only the pace-of-ageing measure changed significantly.
What CALERIE actually did
CALERIE 2 randomised healthy, non-obese adults aged 21 to 50 with a BMI between 22.0 and 27.9 to either 25% calorie restriction or ad-libitum eating, in a 2:1 ratio, for two years. That design detail matters: this was not a weight-loss trial in people with obesity. It was a restriction trial in people who did not need to lose weight, which is what the geroscience hypothesis actually calls for.
Sustained restriction is hard. The prescribed target was 25%; the achieved average was about 11.9%. That shortfall is not a flaw in the trial so much as a finding about feasibility, and it means the results describe roughly 12% restriction, not 25%.
Study snapshot — CALERIE 2
| Design | Randomized controlled trial, 2:1 allocation |
| Participants | Healthy non-obese adults, aged 21–50, BMI 22.0–27.9 |
| Intervention | 25% calorie restriction prescribed; ~11.9% achieved |
| Duration | 2 years |
| Key outcome analysed | DNA methylation measures of biological ageing |
What human studies actually show
The pace-of-ageing result. Waziry and colleagues analysed blood DNA methylation from CALERIE participants using DunedinPACE, an algorithm trained to estimate how fast a person is currently ageing rather than how old they biologically are. The intervention slowed DunedinPACE by 2–3%. The authors noted that effects of this magnitude have been associated in other cohorts with roughly 10–15% lower mortality risk — an association, not a demonstrated outcome in this trial.
The honest counterweight: two clocks did not move. The same analysis found no significant intervention effect on the PC PhenoAge or PC GrimAge methylation clocks. The authors interpreted this as suggesting that dynamic pace-of-ageing measures may be more sensitive to intervention than static biological-age estimates. That is a reasonable interpretation. An equally reasonable one is that when one of three pre-specified measures moves, the finding needs replication before it carries much weight. We take the same cautious view of methylation-based measures generally in our piece on how accurate biological age tests actually are.
Telomeres did not cooperate either. A separate CALERIE 2 analysis examined telomere length and did not produce the clean protective signal that the rodent literature might lead you to expect. Genomic markers of ageing have been inconsistent across this trial, which is itself worth knowing.
The epigenome-wide analysis found no individual sites. A genome-wide methylation analysis across 828,613 CpG sites failed to identify individual sites altered by calorie restriction. Effects appeared only when sets of sites previously linked to BMI, smoking, and age were analysed together — and, notably, restriction shifted age-associated sites in the direction of older age. That is an awkward result that rarely appears in coverage of this trial.
The cardiometabolic findings were more straightforward. Earlier CALERIE publications reported improvements in cardiometabolic risk factors, quality of life, liver measures, and markers of immune function. Those are conventional, expected, and reasonably solid — they are also what you would predict from modest weight loss in healthy people, without needing any ageing-specific mechanism.
What calorie restriction will not do
It will not reliably make you feel more energetic. Sustained energy restriction commonly produces cold intolerance, reduced spontaneous activity, lower libido, and in some people persistent hunger and preoccupation with food. If you are already exhausted, restriction is not the intervention that fixes it, and it may make things worse.
It is not appropriate for everyone, and for some people it is actively unsafe. Anyone with a history of disordered eating, anyone underweight, older adults at risk of sarcopenia, and anyone pregnant or breastfeeding should not pursue deliberate restriction. If food restriction has ever been a difficult area for you, please speak to a clinician before acting on anything in this article.
It has not been shown to extend human lifespan. CALERIE ran for two years and measured surrogates. A follow-up study of participants is examining whether the short-term effects translated into longer-term differences in chronic disease risk, and until that reports, the lifespan question is open.
How this fits with the rest of the ageing toolkit
Calorie restriction reduces mTORC1 signalling and raises AMPK activity, which is the same general direction as pharmacological mTOR inhibition and why the two are often discussed together. It also fits the broader hormesis framework, in which a mild, survivable stressor triggers adaptive responses that leave the organism more robust.
What CALERIE cannot tell you is whether restriction specifically, weight loss generally, or improved metabolic health is doing the work. In non-obese people losing weight over two years, those three things are entangled by design.
Frequently asked questions
How much restriction did people actually manage?
The prescribed target was 25%. The achieved average was about 11.9% over two years, in a highly supported research setting with regular contact and monitoring. That is a useful reality check on what unsupported restriction is likely to look like.
Is a 2–3% slowing of ageing meaningful?
It depends what you compare it to. In observational cohorts, differences of that size on DunedinPACE track with meaningfully different mortality risk. But an association in an observational cohort is not the same as a demonstrated benefit from an intervention, and the effect was not seen on the other two clocks tested.
Does intermittent fasting give the same result?
No trial has tested that. CALERIE restricted total energy intake continuously rather than compressing eating windows. Whether time-restricted eating without net energy reduction produces comparable changes is unstudied at this level of rigour.
Should I try calorie restriction for longevity?
That is a personal decision, and the honest framing is that the demonstrated benefit is small, the burden is high, and the risk is real for some people. If your metabolic health could improve, the cardiometabolic case is clearer than the ageing case.
From Nuvirox
Why we formulated NAD+ Restore
- 500 mg nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
CALERIE is the best human evidence that exists on calorie restriction and ageing, and it delivered a small positive result on one measurement and null results on several others. That is not a debunking — a 2–3% slowing on a validated pace-of-ageing measure in a randomized trial is a real finding, and the geroscience field was right to take note. It is simply much less than the coverage implied, and the divergence between the three clocks is the part most worth remembering.
References
- Waziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging. 2023;3(3):248-257. DOI: 10.1038/s43587-022-00357-y
- Hastings WJ, Ye Q, Wolf SE, et al. Effect of long-term caloric restriction on telomere length in healthy adults: CALERIE 2 trial analysis. Aging Cell. 2024. PMCID: PMC11296136
- Ryan CP, Hayes MG, Lee NR, et al. Epigenome-wide association study analysis of calorie restriction in humans, CALERIE trial analysis. The Journals of Gerontology Series A. 2023. PMCID: PMC9799188
- Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.